12.53

3.84% -0.50

Tonix Pharmaceuticals Holding Corp (TNXP)

Überblick Nachrichten Preisverlauf Financials Warum fällt TNXP? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$13.03

Offen:

$13.07

24-Stunden-Volumen:

504.87K

Relative Volume:

1.04

Marktkapitalisierung:

$199.74M

Einnahmen:

$13.11M

Nettoeinkommen (Verlust:

$-124.02M

KGV:

-0.8786

EPS:

-14.261

Netto-Cashflow:

$-107.25M

1W Leistung:

+1.54%

1M Leistung:

+14.32%

6M Leistung:

-19.06%

1J Leistung:

-70.42%

1-Tages-Spanne:

$12.36

$13.15

1-Wochen-Bereich:

$12.10

$13.19

52-Wochen-Spanne:

$10.03

$69.97

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Firmenname

Tonix Pharmaceuticals Holding Corp

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

212-980-9155

Adresse

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Mitarbeiter

142

Twitter

@TONIXPharma

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TNXP Tonix Pharmaceuticals Holding Corp	12.53	199.74M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-04-18	Eingeleitet	Noble Capital Markets	Outperform
2019-04-18	Hochstufung	ROTH Capital	Neutral → Buy
2017-08-18	Hochstufung	ROTH Capital	Neutral → Buy
2016-09-07	Herabstufung	ROTH Capital	Buy → Neutral
2016-02-17	Bestätigt	Oppenheimer	Outperform
2015-11-04	Eingeleitet	Cantor Fitzgerald	Buy
2015-06-12	Eingeleitet	Oppenheimer	Outperform
2015-02-17	Bestätigt	ROTH Capital	Buy
2014-09-29	Bestätigt	ROTH Capital	Buy

Alle ansehen

Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten

Jul 11, 2026

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits

Jul 11, 2026

Jul 10, 2026

Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits

Jul 10, 2026

Jul 09, 2026

Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr

Jul 09, 2026

Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026

Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan

Jul 09, 2026

Jul 06, 2026

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits

Jul 06, 2026

Jul 02, 2026

Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily

Jul 02, 2026

Jun 30, 2026

Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha

Jun 30, 2026

Jun 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 29, 2026

Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget

Jun 29, 2026

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha

Jun 29, 2026

Tonix enrolls first patient in Phase 2 depression study - grafa.com

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - The Manila Times

Jun 29, 2026

Tonix Pharma Begins Pivotal Phase 2 Depression Trial - TipRanks

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for Major Depressive Disorder - Quiver Quantitative

Jun 29, 2026

Tonix Pharmaceuticals Announces First Patient Enrolled in - GlobeNewswire

Jun 29, 2026

Tonix starts Phase 2 depression trial for TNX-102 SL - Stock Titan

Jun 29, 2026

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (DUS:TPM0) - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (NASDAQ:TNXP) - TradingView

Jun 26, 2026

Jun 25, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (FWB:TPM0) - TradingView

Jun 25, 2026

Enterprise value to EBIT forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Price to sales forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Tonix Pharmaceuticals (TNXP) Receives Strong Buy Rating with $26 Target - GuruFocus

Jun 25, 2026

TNXP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

TNXP Initiated Coverage by Raymond James -- Price Target Set at $26 - GuruFocus

Jun 25, 2026

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy By Investing.com - Investing.com South Africa

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com

Jun 24, 2026

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print - Stocktwits

Jun 24, 2026

Jun 22, 2026